Management of glioblastoma after recurrence: A changing paradigm  by Mallick, Supriya et al.
Journal of the Egyptian National Cancer Institute (2016) 28, 199–210Cairo University
Journal of the Egyptian National Cancer Institute
www.elsevier.com/locate/jnci
www.sciencedirect.comReviewManagement of glioblastoma after recurrence:
A changing paradigm* Corresponding author. Fax: +91 11 26589243.
E-mail address: drsupriyamallick@gmail.com (S. Mallick).
Peer review under responsibility of The National Cancer Institute, Cairo University.
http://dx.doi.org/10.1016/j.jnci.2016.07.001
1110-0362  2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supriya Mallick *, Rony Benson, Abdul Hakim, Goura K. RathDepartment of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, IndiaReceived 15 May 2016; revised 30 June 2016; accepted 3 July 2016
Available online 28 July 2016KEYWORDS
Recurrent;
Glioblastoma;
Re-irradiation;
Bevacizumab;
Chemotherapy;
NovoTTFAbstract Glioblastoma remains the most common primary brain tumor after the age of 40 years.
Maximal safe surgery followed by adjuvant chemoradiotherapy has remained the standard treat-
ment for glioblastoma (GBM). But recurrence is an inevitable event in the natural history of
GBM with most patients experiencing it after 6–9 months of primary treatment. Recurrent GBM
poses great challenge to manage with no well-deﬁned management protocols. The challenge starts
from differentiating radiation necrosis from true local progression. A ﬁne balance needs to be main-
tained on improving survival and assuring a better quality of life. Treatment options are limited and
ranges from re-excision, re-irradiation, systemic chemotherapy or a combination of these.
Re-excision and re-irradiation must be attempted in selected patients and has been shown to
improve survival outcomes. To facilitate the management of GBM recurrences, a treatment algo-
rithm is proposed.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Glioblastoma (GBM) is the most common primary brain can-
cer in the age group after 40 years and the prognosis gets worse
as the age increases. The land mark trial by Stupp et al. led to
acceptance that maximal safe surgery followed by adjuvant
chemoradiotherapy and adjuvant chemotherapy to be the
standard of care [1]. But local inﬁeld recurrence is an inevitable
event, with most patients experiencing it after 6–9 months of
primary treatment because of resistant GBM stem cell and
neuronal stem cells, suboptimal mean dose to the ipsilateral
subventricular zone (SVZ) or involvement of corpus callosum
[2,3]. Different molecular factors like P53 mutation, MIB-1
labeling index, and O-6-methylguanine-DNA methyltrans-
ferase (MGMT) methylation have been correlated with recur-
rence in GBM [4,5]. The various radiation treatment protocols
with dose escalation beyond 60 Gy have been unsuccessful and
have led to increased toxicity. There has been much contro-
versy in the diagnosis of recurrence with the deﬁnitive diagno-
sis only via histopathological examination. But most of the
patients with imaging ﬁnding suggestive of progression may
not be ﬁt for a surgical procedure, making the diagnosis of
recurrent GBM difﬁcult. The main differential diagnosis
includes radiation necrosis which also occurs at the same time
period and may be symptomatic thus mimicking progression.
But the recent advances in imaging have helped us in a great
way in differentiation between the two. The treatment of recur-
rent glial tumors has always been challenging and is associated
with signiﬁcant toxicities and always a balance has to be
achieved between local control and treatment related morbidi-
ties and mortalities [6,7].
Surgery remains an important therapeutic strategy. How-
ever, only a small proportion of patients are found eligible
for a total surgical resection. Re-irradiation (ReRT) has
evolved as a salvage option in the last decade [8]. Evolution
of new radiotherapy techniques and better image guidance
may help in giving highly conformal doses and thus limiting
toxicity. Chemotherapy has also been used by various groups
with an aim to improve survival outcomes. But despite these
various treatment options, outcome of these patients has
remained dismal [9–11]. There has been some recent interest
with some new modalities showing promising results available
for some of these. But the presence of the blood–brain barrier
(BBB) limits the delivery of most chemotherapeutic agents
[12,13]. However, most of the treatment regimens have sur-
faced with single institute retrospective analysis or few phase
II clinical studies. So, there hardly exists any standard treat-ment. In this review we intend to review available investiga-
tions for the diagnosis and treatment modalities with
meaningful impact on survival and derive a possible therapeu-
tic algorithm for patients with recurrent GBM.Search methodology
We searched the PubMed for literature of recurrent glioblas-
toma. We used the following MeSH terminology: recurrent
glioblastoma retrieved 2023 entries; recurrent glioblastoma
AND treatment retrieved 1775 entries (4 phase III, 230 Phase
II, 104 phase I study, 2-metaanalysis). We retrieved a total of
57 articles pertaining to recurrent glioblastoma AND reirradi-
ation but none of these were a phase I/II study. Only 16 found
to describe retrospective result of treating recurrent GBM with
reirradiation. We also searched for recurrent glioblastoma
AND surgery we retrieved 31 entries with one phase II study.
There were 56 entries for the MeSH term of recurrent glioblas-
toma AND vaccine out of which only fourteen described a
phase I/II study. 187 phase I/II and 2 phase III trials described
chemotherapy/targeted therapy for rGBM.
Diagnosis of a recurrence
Diagnosing a recurrence in GBM patients remains a challenge
with radio necrosis closely resembling changes of recurrence
on imaging. Examination of the surgically resected specimen
remains the gold standard for the diagnosis of radiation necro-
sis. The picture is in fact further complicated by coexistence of
both in many cases. The new advances in radiology and
nuclear medicine may help in some cases to differentiate these
entities. A good clinical judgment along information from
these various imaging modalities may help us in majority of
the cases.
Combination of contrast enhanced (CE) T1-weighted imag-
ing, diffusion-weighted (DW) imaging, and perfusion MR
imaging resulted in signiﬁcantly better diagnostic accuracy
without much impact from selection of perfusion MR method
(dynamic CE [DCE]) vs dynamic susceptibility CE) [14]. In
magnetic resonance spectroscopy (MRS) tumor recurrence is
characterized by a higher Choline (Ch)/N-acetylaspartate
(NAA) and Ch/(creatine) Cr ratio but a low NAA/Cr ratio.
Lower lipid signals in MRS are also characteristic of tumor
recurrence. Hence, the presence of elevated lipid signals along
with low choline/NAA ratios may help to differentiate radia-
tion changes from tumor recurrence [15]. Relative cerebral
Table 1 Comparison of imaging characteristics of Recurrent Glioblastoma vs. Radio necrosis.
Radiation necrosis Glioma recurrence
Magnetic Resonance Imaging-
Suggestive features
 Usually in the areas of high dose (>60 Gray)  Can occur anywhere, But inﬁeld recurrence
is the most common
 Contrast enhancement, edema, and mass effect may be seen in both
 Classical Swiss cheese appearance  Unlikely
 Involvement of corpus-callosum or peri-ventricular
white matter
 Less likely
Magnetic Resonance Spectroscopy
[17]
 Low Cho/NAA <1.11
 Low Ch/Cr ratio <1.17
 Elevated lipid signals
 High Cho/NAA >1.11
 High Ch/Cr ratio >1.17
 Low lipid signals
Diﬀusion weighted magnetic
resonance imaging [18]
 Higher apparent diffusion coefﬁcient (ADC)-max-
ima ADC in range of 2.3
 Lower ADC values in range of 1.7
Perfusion magnetic resonance
imaging [19]
 Cerebral blood volume (CBV) <0.6
 Higher fractional anisotropy(FA) values- 0.89
± 0.15
 CBV usually more than 2.6
 Lower fractional anisotropy(FA) values-
0.74 ± 0.14
Positron Emission Tomography  Low metabolic activity  High metabolic activity
Single Photon Emission Computed
Tomography
 Low metabolic activity  High metabolic activity
Management of Glioblastoma after recurrence 201blood volume (CBV) in perfusion images is also helpful to dif-
ferentiate radiation necrosis and recurrence with a high relative
CBV (more than 2.6) for tumor and low CBV (usually <0.6)
for radiation necrosis. Positron emission tomography (PET)
image tumor shows more metabolic activity compared to radi-
ation necrosis. However a low image resolution remains the
limiting factor but this may be overcome with integration of
MRI or computed tomography with PET scans. Tc-GH
SPECT/CT is not inferior to F-FDOPA PET/CT for detection
of recurrence and can be used as a low-cost alternative [16].
The radiological features of radiation necrosis vs. recurrence
of tumor are summarized in Table 1.
Selection of patients for retreatment
A number of factors have been evaluated to correlate with the
prognosis of patients [17–20]. In a recent review Weller et al.
found Karnofsky performance score (KPS) >60, tumor size
<4 cm and progression after >6 months to confer better sur-
vival [20]. These factors may also be helpful in selecting suit-
able patients for treatment also. Those patients who have a
young age, recurrence occurring after 6 months and with good
performance status may be selected for an aggressive
approach. Size of the lesion at the time of recurrence and pres-
ence of symptoms, may be also the factors taken into account
when planning for an aggressive approach. Surgical approach
helps in getting the ﬁnal diagnosis and early relief of symptoms
in the patient.
Surgical salvage
Surgery in recurrent GBM is aimed to reduce the tumor bulk
and achieve symptom relief. It also helps us in the deﬁnitive
diagnosis of a recurrence and repeat morphological and evalu-
ation helps us in evaluating for tumor heterogeneity which is
common in brain tumors. Salvage surgery alone has yielded
short term disease control only and literature authors have
found surgery to increase morbidity in a recurrent setting[20]. However, Bartsch et al. reported improved survival for
patients treated with surgery as a component of the salvage
therapy [21]. In a study by Sughrue et al. it was found that
the median PFS was 7.8 months, 6.0 months, and 4.8 months
following the second, third, and fourth-sixth craniotomies,
respectively [22]. Bloch et al. reported median PFS after re-
surgery: GTR 11.3 month’s vs. STR 6.7 months [23]. They
found that age, performance status and extent of resection at
repeat surgery to be signiﬁcant factors inﬂuencing survival.
Franceschi et al. in a recent series also failed to show a survival
advantage with re-surgery [24].
In the earlier reported studies there was little agreement to
the importance of surgery as salvage treatment and survival
beneﬁt associated with it. The tumor extension to eloquent
areas and lack of intraoperative imaging were drawbacks in
these series. However intraoperative neuro navigation and
use of 5 Aminolevulinic acid (ALA) as guide to resect tumor
helps in reducing the toxicity and improving the tumor control.
In the recently reported series authors have a reported survival
beneﬁt of complete tumor resection which appears appealing
but the better results may be attributable to selection bias.
The principles of surgery in recurrent setting must follow those
of the upfront setting. A maximal safe surgery must be
attempted and intra operative use of ultrasound and cavitron
ultrasonic surgical aspirator must be encouraged. As the
patients get symptom relief and are associated with improved
survival surgical resection must be done in all patients found
suitable based on available evidence. The added advantage is
that a conﬁrmatory diagnosis of tumor recurrence is got.
Re-irradiation
Re-irradiation may be done in patients with small volume
recurrence, if far from the primary area of irradiation, if sur-
gery is not possible due to eloquent location of the tumor.
Another factor that should be assessed before re-irradiation
is the time period of recurrence and ﬁrst irradiation the longer
the interval the better may be the outcome [25]. Re-irradiation
202 S. Mallick et al.has also been tried in surgery to improve outcomes and must
be given to patients who are found suitable. The major issue
with the use of radiation is the anticipation of debilitating tox-
icity in the form of radiation necrosis [25]. The radiation toler-
ance is the most important limiting factor [26]. However, in the
last decade there was a paradigm shift in the understanding
and practice of radiation for recurrent gliomas [26,27].
Re-irradiation may be done by external beam radiotherapy
or by brachytherapy. Most of the published literature on re-
irradiation has used external beam radiotherapy. Newer treat-
ment techniques enable delivery of radiation more precisely to
the target without crossing the tolerance of normal surround-
ing structure [10,28–30]. MRI, SPECT and PET images found
are of real help for target delineation. Sminia et al. recently
reviewed all published data of re-irradiation to compare the
impact of conventional, stereotactic radiotherapy (SRT)/
surgery (SRS) in the management of recurrent glioma [31].
The review compiled the published literature to show that
across different re-irradiation series the dose prescribed ranged
from 20 to 45.5 Gy with recurrence equivalent total dose
(rEQD2) 30–51.3 Gy. The total equivalent radiation dose
(EQD2) was 81.6–102.8 Gy. The PFS ranged from 6.2 to
27.5 months with maximum 6% radiation necrosis [31].
Radio-necrosis in retreated glial tumor is the most fearful com-
plication. However, in the published literature only a handful
of evidence exists reporting radio necrosis. The paucity of true
incidence and its reporting can also be attributed to truncated
follow up. Ramona Mayer et al. in a review correlated radia-
tion necrosis to be commoner with normalized total dose of
more than 100 Gy [25]. Survival after re-irradiation varies
widely with a median DFS 7–9 months reported across the dif-
ferent studies. However, it should be noted that patient char-
acteristic is variable in different cohorts.
The target volume is generally the contrast enhancing tumor
volume that is contoured as the gross tumor volume (GTV). A
5 mm margin around the GTV is generally given to form the
clinical target volume. Whenever possible the MRI of the
patient must be fused to the planning CT for better target delin-
eation. The dose to be prescribed must depend on various fac-
tors like time since the previous irradiation, volume of
recurrence, location of recurrence and dose and fractionation
used in the ﬁrst plan. The other factor that should be taken into
consideration when planning for re-irradiation is the proximity
to the brain stem and optic structures. Generally the cumulative
EQD2 is kept at around 100 Gy. The dose prescribed for re-
irradiation in most of the studies has ranged from 30 Gy to
45 Gy. The dose prescribed should be individualized for each
patient depending on the above mentioned factors.
Although re-irradiation can be tried after a time period of
6 months the ideal case would be a patient recurring after
2 years. The tolerance of various critical structures during re-
irradiation is also an area of great concern and there is a lack
of convincing data on the same. The tolerance of the critical
structures like brain stem and optic structures is usually
reached in the ﬁrst irradiation. The recovery of these neural
structures is not as other organs in the body and is limited.
But there are animal models which have shown good recovery
of these structures. Keeping a cumulative EQD2 of less than
80 Gy for the optic structures and EQD2 of 90 Gy for the
brain stem would be logical for these patients, although con-
vincing data are not available. The EQD2 for the rest of the
brain may be kept below 90–100 Gy. But these should be indi-vidualized for each patient depending on various factors like
dose and fractionation schedule of the ﬁrst irradiation, time
that has elapsed and presence of any radiation changes in
imaging of these patients. This should also take into account
the expected survival of these patients, as these patients with
recurrent GBM are having very poor survival a more liberal
risk of toxicity may be accepted in some patients.
The technique to be used for re-irradiation varies from 3d-
conformal radiotherapy to intensity modulated radiotherapy.
Most of the current published literature uses stereotactic tech-
niques for re-irradiation of these patients. When using 3-D
conformal techniques one should be careful to use a different
ﬁeld arrangement than the one used for initial irradiation.
Generally intensity modulated radiotherapy with good immo-
bilization is preferred for such patients. A summary of the
major trials which have used external beam radiotherapy for
re-irradiation is summarized below in Table 2. Brachytherapy
is also being evaluated as a treatment option for recurrent
GBM. In a large series Kickingereder et al. reported experience
of treating inoperable primary and recurrent glioblastoma with
low-dose rate stereotactic iodine-125 brachytherapy [30]. Med-
ian cumulative surface dose was 60 Gy; and median dose-rate
6 cGy/h. In addition to brachytherapy, 90.3% of patients in
the primary treatment group received external boost radiother-
apy (median dose, 25.2 Gy) and 30.8% received adjuvant
chemotherapy with Temozolomide being the most commonly
used drug. The authors reported impressive 10.5 and
6.2 months median OS and PFS rates respectively and Karnof-
sky performance score, age, and adjuvant chemotherapy were
reported as independent prognostic factors [30]. Archavlis
et al. in another retrospective study compared high dose rate
(HDR) brachytherapy to re-surgery and dose dense temozolo-
mide for recurrent GBM patients. The HDR-brachytherapy
consisted of an after loading 192Ir implant which delivered a
median dose of 40 Gy [32–52] at twice-daily fractions of
5.0 Gy to a CT-MRI fusion-deﬁned planning treatment vol-
ume. The authors reported a median survival 37, 30 and
26 weeks after salvage therapy of the recurrence was, respec-
tively with no added complication in the HDR brachytherapy
group [33].
There is no consensus on what technique is used in re-
irradiation. The poor survival in these patients along with
the invasive nature of brachytherapy leads to external beam
radiotherapy being preferred by most. But brachytherapy is
a very promising form of radiotherapy with good conformal
dose distribution and may be tried in superﬁcial tumors. But
the lack of expertise is a major limiting factor.
The role of adjuvant radiotherapy after re-excision also
remains as an area of conﬂict of interest. There may be beneﬁt
of adjuvant radiotherapy in patients who have undergone a
resection other than a gross total resection. The beneﬁt of
adjuvant radiation after gross total excision remains a debat-
able issue. When planning a patient for re-irradiation the addi-
tional toxicity associated must be kept in mind. There is no
consensus adjuvant radiation and may have role of radiation
and chemo on a case to case basis.Chemotherapy
In the recent years different chemotherapeutic drugs have been
used in patients with recurrent GBM improve disease control
Table 2 Summary of the major trials which have used external beam radiotherapy for re-irradiation.
Study Radiation
technique
Radiation dose Concurrent Survival outcome Toxicity
Henke et al. [26]
n= 31
3d-CRT 20 Gray over 1 week Nil Median overall survival-
10.2 months
No severe toxicity
Niyazi et al. [34]
n= 30
Conventional 36 Gray in 18
fractions
Bevacizumab
Temozolomide
Median survival was
311 days
Wound dehiscence 5%
Grade III DVT 5%
Cho et al. [28]
n= 71
SRS vs. FSRT Median dose
37.5 Gy in 15
fractions -FSRT
17 Gy -SRS
Nil Median OS
11 months - SRS
12 months FSRT
Late complication rate
23%
Worsening of
neurological deﬁcit 41%
Hudes et al. [35]
n= 20
Hypo fractionated
stereotactic
radiotherapy
24–35 Gray at 3.0–
3.5 Gy per fraction
Nil Median OS 10.5 months No grade 3 toxicities
Lederman et al. [36]
n= 88
Fractionated
stereotactic radio
surgery
Four weekly
treatments (median
dose: 6.0 Gy)
Paclitaxel Overall median survival
was 7.0 months
8% incidence of radiation
necrosis
Grosu et al. [10]
n= 44
Fractionated
stereotactic
radiotherapy
Six fractions of 5 Gy Adjuvant
Temozolomide
in 60%
Overall median survival
was 8.0 months
No acute Grade 3/4
neurologic and
hematologic toxicity
Combs et al. [30]
n= 172
Fractionated
stereotactic
radiotherapy
Median dose of
36 Gy
Nil Median overall survival
8 months for patients with
GBM
No higher than grade II
toxicity
Fokas et al. [9]
n= 53
Hypo fractionated
stereotactic
radiotherapy
Median total dose of
30 Gy (20–60 Gy)
Nil Median overall survival
9 months
No higher than grade II
toxicity
Fogh et al. [37]
n= 147
Hypo fractionated
stereotactic
radiotherapy
Median dose, 35 Gy
in 3.5-Gy fractions
Nil Median overall survival
9 months
No severe toxicity
Minniti et al. [38]
n= 36
Fractionated
stereotactic
radiotherapy
7.5 Gy delivered in
15 fractions
Temozolomide Median overall survival
9.7 months
8% incidence of radiation
necrosis
Van Kampen et al.
[39]
n= 27
Stereotactic radio
surgery
17 Gy in one fraction Nil Median survival 9 months No severe toxicity
Biswas et al. [38]
n= 18
Stereotactic radio
surgery
10–20 Gy in one
fraction
Nil Median survival
6.7 months
No higher than grade II
acute side eﬀects
Patel et al. [41]
n= 18
SRS or FSRT FSRT-36 Gy in six
fraction
SRS-18 Gy (range:
12–20 Gy) in one
fraction
Nil Median OS
8.5 months - SRS
7.4 months FSRT
No severe toxicity
Management of Glioblastoma after recurrence 203[10,34]. A wide range of chemotherapy and targeted drugs
failed to show any beneﬁt in phase I/II studies and limited
phase III studies as well (Table 3). Temozolomide, Beva-
cizumab, Nitrosureas are the agents that have shown moderate
activity in the treatment of recurrent GBM and further discus-
sion will be on these efﬁcacious regimens only. The patient
must be also assessed thoroughly before starting chemotherapy
in these patients with special attention to KPS, presence of
co-morbidities. The patients who have undergone a surgical
excision must undergo an immunohistochemical study for
the various predictive factors like MGMT methylation which
also help us in tailoring treatment. The chemotherapy may
be given alone or after surgery or along with and after radio-
therapy in suitable patients.
Bevacizumab
Glioblastomas are highly vascularized tumors in which the
vascular endothelial growth factor (VEGF) signaling pathway
is upregulated. Bevacizumab is a humanized monoclonalantibody against circulating VEGF. Several phase I/II studies
reported high responses and improved 6-month progression-
free survival with Bevacizumab. Based on these results Beva-
cizumab, a vascular endothelial growth factor inhibitor
received FDA approval for use in recurrent gliomas. Subse-
quently, a better planned randomized phase 2 BRAIN trial
investigated bevacizumab alone and in combination with
irinotecan did not show a convincing beneﬁt of Bevacizumab
compared with historical series [42]. The trial randomly allo-
cated 167 patients with ﬁrst or second relapse to receive
Bevacizumab monotherapy or in combination with Irinote-
can. The primary end points were 6-months PFS and overall
response rate. The trial reported 6 months PFS 42.6% and
50.3% in the monotherapy and combination arm, and
ORR 28.2% and 37.8% respectively. Median Overall survival
was 9.2 months and 8.7 months respectively. Subsequently
two metaanalysis established 6-month progression-free sur-
vival rates 38–45% and median time to tumor progression
6.1 months. Addition of Irinotecan failed to improve survival
Table 3 Summarizes different agents used for the treatment of rGBM alone or in combination failed to achieve signiﬁcant response in
phase I/II/III trials.
Drug/Phase Type of drug
Verubulin/Phase II Microtubule destabilizer and Vascular disrupting agent
Erlotinib + temsirolimus/PhaseII Epidermal growth factor receptor (EGFR) and the
mechanistic target of rapamycin (mTOR)
Sunitinib/Phase II Inhibitor of several receptor tyrosine kinases
Fotemustine/Phase I; Phase II VEGF inhibitor with Nitrosurea
Enzastaurin/Phase II, Phase III Selective oral inhibitor of protein kinase Cb
Cediranib/Phase III [monotherapy or in combination
with Lomustine]
Vascular endothelial growth factor receptor (VEGFR)
tyrosine kinase inhibitor
Dasatinib/Phase II Multitargeted tyrosine kinase inhibitor
Bosutinib/Phase II Kinase inhibitor of Src and Abl
Cilengitide/Phase II av integrin antagonist
CT-322/Phase II Inhibitor of VEGFR-2
Veliparib/Phase I PARP inhibitor
Pazopanib + Lapatinib/Phase II Antiangiogenic pazopanib; ErbB inhibitor lapatinib
Gimatecan/Phase II Lipophilic oral camptothecin analog
Nintedanib/Phase II Triple angiokinase inhibitor
Vandetanib/Phase II Multi targeted tyrosine kinase inhibitor
Patupilone/Phase II Natural microtubule-stabilizing cytotoxic agent
Vorinostat/Phase II; Romidepsin/Phase II Histone deacetylase (HDAC) inhibitor
TLN-4601/Phase II Ras-MAPK signaling pathway inhibitor
Aﬂibercept/Phase II VEGF Trap
Sagopilone/Phase II Lipophylic and synthetic analog of epothilone B
Rilotumumab/Phase II A fully human monoclonal antibody against hepatocyte
growth factor/scatter factor (HGF/SF)
Imatinib + hydroxyurea/Phase II Protein-tyrosine kinase inhibitor that inhibits the BCR-ABL
tyrosine kinase
Didemnin B/Phase II Natural product derived from the Caribbean Tunic inhibit all
phases of the cell cycle
Induces rapid and wholesale apoptosis through dual inhibition
of PPT1 and EEF1A1
KRN8602(MX2)/Phase II A novel morpholino anthracycline with capacity to cross BBB
Thalidomide/Phase II Putative inhibitor of angiogenesis
Paclitaxel/Phase II Enhances the polymerization of tubulin to stable microtubules
Cystemustine/Phase II Nitrosourea
Marimastat/Phase II Matrix metalloproteinase inhibitor
XR5000/Phase II Tricyclic carboxamide that intercalates DNA and inhibits
both topoisomerase I and II
Geﬁtinib/Phase II; Erlotinib/Phase II Epidermal growth factor receptor tyrosine kinase inhibitor
Cloretazine/Phase II Novel alkylating agent belonging to 1,2-bis(sulfonyl)
hydrazines class
Cetuximab/Phase II Anti EGFR monoclonal Antibody
Trabedersen/Phase II TGF-b2 inhibitor
Bortezomib/Phase II Proteasome inhibitor
Convection-enhanced delivery (CED) of cintredekin besudotox
(CB) was compared with Gliadel wafers (GW)/Phase III
Nitrosurea in Wafer
204 S. Mallick et al.but increased the rate of treatment discontinuation [43,44].
The metaanalysis found no difference in bevacizumab dose–
response beneﬁt between 5 mg/kg and 10 to 15 mg/kg. In
an interesting revelation Piccioni et al. reported non-inferior
outcome with deferred use of bevacizumab in recurrent
GBM [45]. In addition discontinuation of Bevacizumab for
reason other than tumor progression appears not to adversely
affect patient’s outcome [46]. This ﬁnding may have an
impact in curtailing the cost of care as well. Several phase
I/II studies have attempted to combine Bevacizumab with
Irinotecan, carboplatin, panobinostat, sorafenib, tem-
sirolimus, Bortezomib, Geﬁtinib, Erlotinib, Cetuximab,
Lenalidomide, Nintedanib, and Veliparib but failed to show
improved outcome [47–51].Nitrosureas
There is also few published literature reporting the efﬁcacy of
Nitrosureas in recurrent GBM. These were generally retro-
spective series or phase II studies. Hence the phase II BELOB
trial randomly allocated 153 patients with recurrent GBM to
treatment with oral lomustine 110 mg/m2 once every 6 weeks,
intravenous bevacizumab 10 mg/kg once every 2 weeks, or
combination treatment with lomustine 110 mg/m2 every
6 weeks and bevacizumab 10 mg/kg every 2 weeks [52]. How-
ever, lomustine dose was reduced to 90 mg/m2 following high
rate of grade III/IV thrombocytopenia. The primary endpoint
was overall survival at 9 months, analyzed by intention to
treat. The trial reported a median survival of 4 months in the
combination arm compared to 3 and 1 month in the
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41%, 16%, 13% and median OS was 11, 8, 8 months respec-
tively in the combination arm and the Bevacizumab or Lomus-
tine monotherapy arm. This trial established an important
combination regimen of the Bevacizumab with Lomustine
which merits evaluation in phase III study. In addition the sur-
vival curves of the two monotherapy arm appear superim-
posed over each other and there by establish equal
effectiveness as monotherapy and may be used in a tailored
therapy. Another phase II AVAREG trial randomized patients
to receive bevacizumab (BEV) or fotemustine (FTM). The pri-
mary end point OS at 6 months was 62% and 73% for beva-
cizumab and fotemustine, respectively. OS9 (47% and 38%),
and median OS (8.7 and 7.2 months) was similar between fote-
mustine and bevacizumab arms [53]. These ﬁndings are also
not different to that of the BELOB trial.
Temozolomide
Metronomic Temozolomide has long been considered as an
important therapeutic option for recurrent GBM. Different
dose schedules 50 mg/m2 daily, 120 mg/m2 one week on and
one week off or 80 mg/m2 three weeks on and one week off
have been used. In a well-designed phase II RESCUE trial
metronomic dose of Temozolomide was used for recurrent
glioma. The study revealed signiﬁcant survival beneﬁt for
patients recurring during the course of adjuvant Temozolo-
mide or after longer interval [54]. Grosu et al. in a series of
44 patients administered Temozolomide to 29 patients. Temo-
zolomide was administered one-two cycles before and four to
ﬁve cycles after re-irradiation [10]. Unlike other studies evalu-
ating chemotherapy, Grosu et al. reported signiﬁcantly
improved survival both in univariate and multivariate analysis.
Re-challenge with Temozolomide was further evaluated in a
phase II randomized DIRECTOR Trial [55]. Patients with
glioblastoma at ﬁrst progression after Temozolomide/Radio-
therapy? Temozolomide and at least two maintenance temo-
zolomide cycles were randomized to one week on (120 mg/m2
per day)/one week off or 3 weeks on (80 mg/m2 per day)/one
week off. Primary endpoint was median time to-treatment fail-
ure (TTF). The trial was closed prematurely after 105 patents.
Median TTF (1.8 vs. 2 months) and OS (9.8 vs. 10.6 months)
were not different between the two arms. The ﬁndings support
both the regimens of metronomic temozolomide. In addition
median TTF was 3.2 months for MGMT methylated tumors
compared to 1.8 months in unmethylated tumors. Han et al.
evaluated the dose dense temozolomide for recurrent GBM
reported modest 10% PFS-6 with median OS of 21.6 weeks
[56]. However exploratory analysis revealed median PFS
7.57 weeks in patients with unmethylated MGMT and median
OS 19.4 weeks compared to 11.57 weeks and 65.3 weeks for
patients with methylated MGMT. This points to an important
fact that patients with MGMT methylation are candidates for
salvage metronomic temozolomide but MGMT unmethylated
patients should be considered for an alternative treatment
approach. Attempts to incorporate Irinotecan or other
chemotherapeutic agents failed to improve survival [57].
Thus based on current available literature Bevacizumab or
Nitrosureas may be used as single agents in patients with
recurrent GBM. Based on the current literature the choice
must be based on expected toxicity and cost issues. A combi-
nation of Bevacizumab and Nitrosureas may be used inpatients with good performance status and good expected tol-
erance. Re-challenge with Temozolomide is also a valid option
and is of maximum beneﬁt in patients with MGMT methyla-
tion. The decision to use chemotherapy thus needs to be per-
sonalized regarding the agent, the dose and duration. The
chemotherapy may be continued till progression of disease
or till when severe toxicity appears.
The patients who undergo surgery may also be considered
for adjuvant chemotherapy, with special attention to the vari-
ous molecular predicative markers in the specimen. The
patients with MGMT methylation in the resected specimen
may beneﬁt from adjuvant Temozolomide. Bevacizumab must
be also used with caution in patients in the immediate post-
operative time due to complications of delayed wound healing
and lack of evidence of it in the adjuvant setting in re-excised
patients. The duration for which the agent must be given is
also debatable and there is a lack of any consensus on the
same. But if the patient has undergone a biopsy or decompres-
sion only chemotherapy may continue till progression.
The addition of Temozolomide with radiotherapy in the re-
irradiation setting also merits evaluation. The beneﬁt of concur-
rent Temozolomide in the primary setting may be extrapolated
in the recurrent setting and it is logical to use it in re-irradiation
setting also. There are studies reporting the feasibility of con-
current Temozolomide in the concurrent setting, although stud-
ies evaluating the speciﬁc question are lacking. The adjuvant
chemotherapy after re-irradiation may follow the principles of
adjuvant chemotherapy after re-excision.
A possible treatment algorithm for recurrent GBM is
depicted in Fig. 1.
Novel treatment techniques
NovoTTF is a portable device delivering low-intensity, inter-
mediate frequency electric ﬁelds via non-invasive, transducer
arrays. The electric ﬁelds interfere with cell division by causing
misalignment of microtubule subunits in the mitotic spindle
during the metaphase to anaphase transition and by dielec-
trophoretic movement of intracellular macromolecules and
organelles during telophase. Kirson et al. reported encouraging
26.1 weeks median time to disease progression and 62.2 weeks
median overall survival and paved for a phase III trial [58].
The trial randomized recurrent GBM patients to NovoTTF
(20–24 h/day) or chemotherapy of physician’s choice with Pri-
mary endpoint of improvement of overall survival. The trial
randomly allocated 237 patients to the study and experimental
arm. Patient characteristics were well balanced between the two
groups. Median survival was 6.6 months in the experimental
arm and 6.0 in the chemotherapy arm, progression-free survival
rate at 6 months was 21.4% and 15.1% (p= 0.13). Responses
were more common in the TTF arm (14% versus 9.6%,
p= 0.19). The TTF-related adverse events were mild (14%)
to moderate (2%). Severe adverse events occurred in 6% and
16% (p= 0.022) of patients treated with TTF and chemother-
apy, respectively. Quality of life analyses was also favorable in
the TTF arm [59]. Though the trial did not ﬁnd a superiority of
the TTF over chemotherapy it must be considered an equiva-
lent and less toxic treatment options for these patients. The
radiological response which is becoming more a synonym with
treatment response for recurrent GBM also favors TTF.
Recently a post hoc analysis reported signiﬁcantly higher OS
Figure 1 Possible treatment algorithm for recurrent GBM.
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BPC (7.7 v 5.9 months). Additional post hoc analysis showed
signiﬁcantly higher median OS with NovoTTF Therapy than
with BPC for patients with prior low-grade glioma, tumor size
P18 cm, Karnofsky performance status P80, and those who
had previously failed Bevacizumab therapy [60]. These ﬁndings
are quite encouraging but should be considered hypothesis gen-
erating and may be validated in a prospective trial.
Impact of anti-epileptic drugs
In the last decade preclinical studies have suggested that val-
proic acid (VPA) and its analogs could affect tumor cells in
many respects, such as inhibition of a subset of histone
deacetylases (HDAC) and cellular kinases, which could affect
gene transcription through histone hyper acetylation, DNA
hypo-methylation, and modulation of the MAP Kinase signal-
ing pathway [61]. As a result VPA could inhibit tumor angio-
genesis and induce differentiation and apoptosis in different
types of tumor cells. In addition, clinical studies also have
reported prolonged survival in patients with GBM when trea-
ted with valproic acid for seizure prophylaxis or treatment [62].
A recently published meta-analysis conﬁrmed the beneﬁt of
treatment with VPA (HR, 0.56; 95% CI, 0.44–0.71) [63].
Another recent study evaluated the beneﬁcial role of Levetirac-
etam in the seizure management or patients with GBM
reported encouraging 2.5 months improved PFS for patients
receiving LVE for at least a period of three months. This leads
researchers to initiate phase II study to evaluate the impact of
the anti-epileptic drug (AED) in GBM. In recurrent GBM also
the use of AED plays a crucial role and may derive survival
beneﬁt [64]. In a recent update Happold et al. conducted a
pooled analysis of survival association of AED use at the start
of chemoradiotherapy with temozolomide but found no asso-
ciation of PFS and OS advantage for patients taking either
VPA or levetiracetam [65]. However, there is much criticism
to the pooled analysis as it is also a retrospective study onlyof many studies which were not intended to answer the ques-
tion [66].
Similar to AED steroid plays an important role in the man-
agement of recurrent GBM also. Dexamethasone is one of the
commonly used drugs for these patients to help in reducing
symptoms. However, in an exploratory analysis of the
NovoTTF trial researchers found a negative impact of using
more than 4.1 mg of dexamethasone daily.
Management of recurrent GBM in elderly and pediatric patients
Management of elderly patients with GBM itself is a challenge
and is evolving from conventional radiation with concurrent
temozolomide to hypofractionated radiation alone or temo-
zolomide alone. However, outcome remains dismal even after
any of the treatment approach. However, the management of
recurrent GBM poses further challenge as the patients have
limited life expectancy and propensity for high rate of compli-
cation. Interestingly retrospective data show no increased rate
of complication in these patients and median survival for the
reoperation group, single-surgery group, and biopsy only
group were 18.4, 8.9, and 3.4 months, respectively [67]. Socha
et al. analyzed data of 98 elderly frail recurrent GBM patients
[68]. Median overall survival from randomization for all
patients was 35 weeks and 55 versus 30 weeks for any treatment
versus best supportive care (BSC). Median post-progression
survival was 15 weeks in the entire cohort and 23 weeks with
any treatment versus 9 weeks with BSC. In addition, local treat-
ment (surgery and/or RT) leads to better median PPS of 51 ver-
sus 21 weeks for chemotherapy. In patients with poor KPS at
relapse median PPS was 9 weeks with BSC versus 21 weeks with
any treatment.
Management of newly diagnosed pediatric GBM is another
area of concern because of anticipated long term toxicity and
concurrent radiation with temozolomide is considered stan-
dard [69,70]. However, data are extremely sparse regarding
the management of recurrent GBM. However, given the poor
Management of Glioblastoma after recurrence 207outcome treatment option may follow the approach of adult
patients.
Quality of life
Assessment of Quality (QOL) of life and reporting of QOL are
areas of unmet need. Presently available therapies are associ-
ated with limited survival of less than 12 months. Hence, cost
of care and quality of life assessment becomes important for
advocating any modality. However, there is limited informa-
tion on the humanistic burden among patients with recurrent
GBM. Only a few studies reported QOL and showed improve-
ment in QOL. Recently Signorovitch et al. conducted a system-
atic review of Overall Survival, QOL, and Neurocognitive
function in rGBM [71]. The authors found very limited data
about QOL in rGBM and concluded worse baseline QoL
among patients with rGBM than among the general popula-
tion and patients with other cancers. Most importantly the
authors reported no improvement in QOL with the presently
evaluated treatment options. Bevacizumab alone or in combi-
nation also failed to improve QOL [51]. NovoTTF is the only
intervention with favorable QOL over chemotherapy in most
domains, possibly due to the absence of treatment related tox-
icities [59].
Future directions
In a pioneering work Verhaak et al. established four different
classes of GBM viz., proneural, neural, classical and mes-
enchymal subtypes with distinct molecular aberration and clin-
ical behavior. The Classical subtype is characterized by
Chromosome 7 ampliﬁcation paired with chromosome 10 loss,
and fourfold increase in EGFR expression and lack of p53
mutation. The proneural class shows alterations of PDGFRA
and IDH1 mutations. Mesenchymal subtype is characterized
by lower NF1 expression, whereas neural subtype shows
expression of neuron markers such as NEFL, GABRA1,
SYT1 and SLC12A5 [72]. In an interesting revelation Li
et al. show a wide difference in the pattern of molecular aber-
ration in primary and recurrent GBM. The authors reported
Gene set enrichment analysis revealed that chromatin fracture,
repair, and remodeling genes were enriched in recurrent
glioblastoma [73]. Majority solid tumors are characterized by
increased glucose uptake which may be reﬂected by elevated
glycolysis even in the presence of oxygen (aerobic glycolysis,
the Warburg effect). Preclinical models have shown glioma
growth inhibition with reduction in dietary carbohydrates.
Feasibility trials are evaluating low-carbohydrate, ketogenic
diet containing plant oils for patients with recurrent GBM
with encouraging early results [74,75].
In the recent years the efﬁcacy of immunotherapy for can-
cer has been validated. A wide range of drugs viz. dendritic cell
cancer vaccine, Heat-shock protein peptide complex-96 vacci-
nation, humanized monoclonal antibody against the cytotoxic
T-lymphocyte antigen-4 (CTLA-4) immune checkpoint, block-
ade of programed death 1 (PD-1) and its ligand PD-L1 as well
as bioengineered chimeric antigen-receptor T cells has shown
appealing response in the treatment of different cancers. Early
clinical trials are ongoing with these agents and the results of
these trials are eagerly awaited. In one the recent studies
Schuessler et al. reported possible survival beneﬁt in recurrentGBM when treated with autologous cyto-megalo virus-speciﬁc
T cells and chemotherapy [76]. These may prove to be beneﬁ-
cial in future trials in recurrent GBM.
Conclusions
Recurrent GBM is a challenge to manage with dismal progno-
sis. Treatment of rGBM requires a delicate balance between
aggressiveness of treatment, outcome, cost of care and quality
of life. Surgery, re-irradiation and systemic chemotherapy pro-
vide short term disease control and modest survival. Younger
patients with preserved performance status should be offered
Surgery followed by reirradiation or additional salvage
chemotherapy, whereas patients with smaller primary in elo-
quent location and recurrence after long time after primary
radiation should be considered for salvage reirradiation along
with chemotherapy. MGMT methylation guides to decide
between Temozolomide and bevacizumab. Newer targeted
therapy, novel treatment technique like NovoTTF,
immunotherapy holds promise to impart better survival with-
out compromising on the quality of life.
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